[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fDUPgzYbUrOw3C7OGsHkvSrxpqipNiKeYq0cp0dHPZ5I":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":84,"rows":91},"Massachusetts Eye and Ear Infirmary",[4],98,false,28,6,11524,17,54,[14,17,20,22,24,27,29,31],{"name":15,"count":16},"Glaucoma",7,{"name":18,"count":19},"Spasmodic Dysphonia",4,{"name":21,"count":19},"Vestibular Disorder",{"name":23,"count":19},"Vestibular Schwannoma",{"name":25,"count":26},"Homonymous Hemianopia",3,{"name":28,"count":26},"Stevens-Johnson Syndrome",{"name":30,"count":26},"Ptosis, Eyelid",{"name":32,"count":26},"Rhegmatogenous Retinal Detachment",[34,39,44,49,54,59,64,69,74,79],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT04321954","Lenvatinib in Locally Advanced Invasive Thyroid Cancer","2025-05-27","LENVATINIB",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT04440280","Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy","2026-04-29","N-acetyl cysteine (NAC) 10% solution",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT05331664","Dropless Pars Plana Vitrectomy Study","2026-07-25","Triamcinolone Acetonide 40mg\u002FmL",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT03079999","Study of Aspirin in Patients With Vestibular Schwannoma","2026-08","Aspirin",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT06033703","Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment","2026-09","Netarsudil Ophthalmic",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT05521048","Doxycycline in Cutaneous Schwannoma (NF2)","2026-09-01","Doxycycline Injection [Doxy]",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT06425419","The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy","2026-12-01","Topotecan",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT07383701","Lactiplantibacillus Plantarum 299v Probiotic Supplementation in Patients With Diabetic Macular Edema","2027-03-01","Lactobacillus plantarum 299v",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT04735263","Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD","2027-04-01","Atorvastatin 80mg",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT06926478","Subconjunctival Humira for Boston Keratoprosthesis","2027-06-01","Adalimumab",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,119,137,155,173,208,230,253,276,299,323,341,359,381,415,439,460,486,511,542,560,585,603,632,650,668,693,718,736,765,783,801,846,884,908,938,956,981,999,1021,1048,1066,1084,1107,1132,1157,1185,1203,1228,1253,1271,1296,1314,1341,1366,1391,1415,1433,1457,1487,1505],{"intervention":48,"totalTrials":93,"cells":94},1,{"EARLY_PHASE1":95,"PHASE1":98,"PHASE2":100,"PHASE3":102,"PHASE4":104,"NA":117},{"trials":96,"activeCount":97},[],0,{"trials":99,"activeCount":97},[],{"trials":101,"activeCount":97},[],{"trials":103,"activeCount":97},[],{"trials":105,"activeCount":93,"soonestReadout":47},[106],{"nctId":45,"briefTitle":46,"status":107,"phases":108,"primaryCompletion":47,"completion":109,"start":110,"enrollment":111,"conditions":112,"interventions":113},"RECRUITING",[89],"2027-01-30","2022-07-25",168,[32],[48,114,115,116],"Moxifloxacin 0.5% or Polymyxin\u002FTrimethoprim if patient is allergic to moxifloxacin","Prednisolone 1%","Atropine 1%",{"trials":118,"activeCount":97},[],{"intervention":114,"totalTrials":93,"cells":120},{"EARLY_PHASE1":121,"PHASE1":123,"PHASE2":125,"PHASE3":127,"PHASE4":129,"NA":135},{"trials":122,"activeCount":97},[],{"trials":124,"activeCount":97},[],{"trials":126,"activeCount":97},[],{"trials":128,"activeCount":97},[],{"trials":130,"activeCount":93,"soonestReadout":47},[131],{"nctId":45,"briefTitle":46,"status":107,"phases":132,"primaryCompletion":47,"completion":109,"start":110,"enrollment":111,"conditions":133,"interventions":134},[89],[32],[48,114,115,116],{"trials":136,"activeCount":97},[],{"intervention":115,"totalTrials":93,"cells":138},{"EARLY_PHASE1":139,"PHASE1":141,"PHASE2":143,"PHASE3":145,"PHASE4":147,"NA":153},{"trials":140,"activeCount":97},[],{"trials":142,"activeCount":97},[],{"trials":144,"activeCount":97},[],{"trials":146,"activeCount":97},[],{"trials":148,"activeCount":93,"soonestReadout":47},[149],{"nctId":45,"briefTitle":46,"status":107,"phases":150,"primaryCompletion":47,"completion":109,"start":110,"enrollment":111,"conditions":151,"interventions":152},[89],[32],[48,114,115,116],{"trials":154,"activeCount":97},[],{"intervention":116,"totalTrials":93,"cells":156},{"EARLY_PHASE1":157,"PHASE1":159,"PHASE2":161,"PHASE3":163,"PHASE4":165,"NA":171},{"trials":158,"activeCount":97},[],{"trials":160,"activeCount":97},[],{"trials":162,"activeCount":97},[],{"trials":164,"activeCount":97},[],{"trials":166,"activeCount":93,"soonestReadout":47},[167],{"nctId":45,"briefTitle":46,"status":107,"phases":168,"primaryCompletion":47,"completion":109,"start":110,"enrollment":111,"conditions":169,"interventions":170},[89],[32],[48,114,115,116],{"trials":172,"activeCount":97},[],{"intervention":58,"totalTrials":174,"cells":175},2,{"EARLY_PHASE1":176,"PHASE1":190,"PHASE2":192,"PHASE3":202,"PHASE4":204,"NA":206},{"trials":177,"activeCount":97},[178],{"nctId":179,"briefTitle":180,"status":181,"phases":182,"primaryCompletion":183,"completion":184,"start":185,"enrollment":186,"conditions":187,"interventions":189},"NCT04752020","Netarsudil Use After Descemtorhexis Without Endothelial Keratoplasty","COMPLETED",[85],"2023-06-28","2023-12-30","2021-03-28",25,[188],"Fuchs' Endothelial Dystrophy",[58],{"trials":191,"activeCount":97},[],{"trials":193,"activeCount":93,"soonestReadout":57},[194],{"nctId":55,"briefTitle":56,"status":107,"phases":195,"primaryCompletion":57,"completion":196,"start":197,"enrollment":198,"conditions":199,"interventions":201},[86,87],"2026-12","2025-01-14",48,[32,200],"Proliferative Vitreoretinopathy",[58],{"trials":203,"activeCount":97},[],{"trials":205,"activeCount":97},[],{"trials":207,"activeCount":97},[],{"intervention":63,"totalTrials":93,"cells":209},{"EARLY_PHASE1":210,"PHASE1":212,"PHASE2":214,"PHASE3":224,"PHASE4":226,"NA":228},{"trials":211,"activeCount":97},[],{"trials":213,"activeCount":97},[],{"trials":215,"activeCount":93,"soonestReadout":62},[216],{"nctId":60,"briefTitle":61,"status":217,"phases":218,"primaryCompletion":62,"completion":196,"start":219,"enrollment":220,"conditions":221,"interventions":223},"ACTIVE_NOT_RECRUITING",[86,87],"2022-09-19",19,[222],"Neurofibromatosis Type 2",[63],{"trials":225,"activeCount":97},[],{"trials":227,"activeCount":97},[],{"trials":229,"activeCount":97},[],{"intervention":53,"totalTrials":93,"cells":231},{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":236,"PHASE3":247,"PHASE4":249,"NA":251},{"trials":233,"activeCount":97},[],{"trials":235,"activeCount":97},[],{"trials":237,"activeCount":93,"soonestReadout":52},[238],{"nctId":50,"briefTitle":51,"status":217,"phases":239,"primaryCompletion":52,"completion":240,"start":241,"enrollment":242,"conditions":243,"interventions":246},[87],"2029-02","2018-06-11",97,[23,244,245],"Acoustic Neuroma","Neurofibromatosis 2",[53],{"trials":248,"activeCount":97},[],{"trials":250,"activeCount":97},[],{"trials":252,"activeCount":97},[],{"intervention":73,"totalTrials":93,"cells":254},{"EARLY_PHASE1":255,"PHASE1":257,"PHASE2":259,"PHASE3":270,"PHASE4":272,"NA":274},{"trials":256,"activeCount":97},[],{"trials":258,"activeCount":97},[],{"trials":260,"activeCount":93,"soonestReadout":72},[261],{"nctId":70,"briefTitle":71,"status":262,"phases":263,"primaryCompletion":72,"completion":264,"start":265,"enrollment":266,"conditions":267,"interventions":269},"NOT_YET_RECRUITING",[87],"2027-09-01","2026-08-01",36,[268],"Diabetic Macular Edema",[73],{"trials":271,"activeCount":97},[],{"trials":273,"activeCount":97},[],{"trials":275,"activeCount":97},[],{"intervention":38,"totalTrials":93,"cells":277},{"EARLY_PHASE1":278,"PHASE1":280,"PHASE2":282,"PHASE3":293,"PHASE4":295,"NA":297},{"trials":279,"activeCount":97},[],{"trials":281,"activeCount":97},[],{"trials":283,"activeCount":93,"soonestReadout":37},[284],{"nctId":35,"briefTitle":36,"status":217,"phases":285,"primaryCompletion":37,"completion":286,"start":287,"enrollment":288,"conditions":289,"interventions":292},[87],"2026-05-27","2021-03-09",30,[290,291],"Differentiated Thyroid Cancer","Advanced Cancer",[38],{"trials":294,"activeCount":97},[],{"trials":296,"activeCount":97},[],{"trials":298,"activeCount":97},[],{"intervention":43,"totalTrials":93,"cells":300},{"EARLY_PHASE1":301,"PHASE1":303,"PHASE2":305,"PHASE3":317,"PHASE4":319,"NA":321},{"trials":302,"activeCount":97},[],{"trials":304,"activeCount":97},[],{"trials":306,"activeCount":93,"soonestReadout":42},[307],{"nctId":40,"briefTitle":41,"status":107,"phases":308,"primaryCompletion":42,"completion":309,"start":310,"enrollment":311,"conditions":312,"interventions":314},[87],"2027-04-30","2020-09-16",45,[313],"Fuchs Endothelial Corneal Dystrophy",[43,315,316],"N-acetyl cysteine (NAC) 20% solution","Visine Dry Eye Relief eye drops",{"trials":318,"activeCount":97},[],{"trials":320,"activeCount":97},[],{"trials":322,"activeCount":97},[],{"intervention":315,"totalTrials":93,"cells":324},{"EARLY_PHASE1":325,"PHASE1":327,"PHASE2":329,"PHASE3":335,"PHASE4":337,"NA":339},{"trials":326,"activeCount":97},[],{"trials":328,"activeCount":97},[],{"trials":330,"activeCount":93,"soonestReadout":42},[331],{"nctId":40,"briefTitle":41,"status":107,"phases":332,"primaryCompletion":42,"completion":309,"start":310,"enrollment":311,"conditions":333,"interventions":334},[87],[313],[43,315,316],{"trials":336,"activeCount":97},[],{"trials":338,"activeCount":97},[],{"trials":340,"activeCount":97},[],{"intervention":316,"totalTrials":93,"cells":342},{"EARLY_PHASE1":343,"PHASE1":345,"PHASE2":347,"PHASE3":353,"PHASE4":355,"NA":357},{"trials":344,"activeCount":97},[],{"trials":346,"activeCount":97},[],{"trials":348,"activeCount":93,"soonestReadout":42},[349],{"nctId":40,"briefTitle":41,"status":107,"phases":350,"primaryCompletion":42,"completion":309,"start":310,"enrollment":311,"conditions":351,"interventions":352},[87],[313],[43,315,316],{"trials":354,"activeCount":97},[],{"trials":356,"activeCount":97},[],{"trials":358,"activeCount":97},[],{"intervention":78,"totalTrials":93,"cells":360},{"EARLY_PHASE1":361,"PHASE1":363,"PHASE2":365,"PHASE3":375,"PHASE4":377,"NA":379},{"trials":362,"activeCount":97},[],{"trials":364,"activeCount":97},[],{"trials":366,"activeCount":93,"soonestReadout":77},[367],{"nctId":75,"briefTitle":76,"status":107,"phases":368,"primaryCompletion":77,"completion":369,"start":370,"enrollment":371,"conditions":372,"interventions":374},[87],"2028-01-01","2021-02-04",21,[373],"Age-related Macular Degeneration",[78],{"trials":376,"activeCount":97},[],{"trials":378,"activeCount":97},[],{"trials":380,"activeCount":97},[],{"intervention":382,"totalTrials":174,"cells":383},"Dexamethasone",{"EARLY_PHASE1":384,"PHASE1":386,"PHASE2":388,"PHASE3":399,"PHASE4":401,"NA":403},{"trials":385,"activeCount":97},[],{"trials":387,"activeCount":97},[],{"trials":389,"activeCount":93,"soonestReadout":394},[390],{"nctId":391,"briefTitle":392,"status":107,"phases":393,"primaryCompletion":394,"completion":394,"start":395,"enrollment":9,"conditions":396,"interventions":398},"NCT04225611","Therapeutic Contact Lens Drug Delivery System (TCL-DDS) in Patients With Recurrent Cystoid Macular Edema",[86,87],"2027-12-31","2021-03-15",[397],"Cystoid Macular Edema",[382],{"trials":400,"activeCount":97},[],{"trials":402,"activeCount":97},[],{"trials":404,"activeCount":97},[405],{"nctId":406,"briefTitle":407,"status":181,"phases":408,"primaryCompletion":409,"completion":409,"start":410,"enrollment":411,"conditions":412,"interventions":414},"NCT01415583","Evaluating Perioperative Dexamethasone and the Risk of Bleeding in Tonsillectomy",[90],"2011-11","2010-07",314,[413],"Post-operative Hemorrhage",[382],{"intervention":83,"totalTrials":93,"cells":416},{"EARLY_PHASE1":417,"PHASE1":419,"PHASE2":431,"PHASE3":433,"PHASE4":435,"NA":437},{"trials":418,"activeCount":97},[],{"trials":420,"activeCount":93,"soonestReadout":82},[421],{"nctId":80,"briefTitle":81,"status":262,"phases":422,"primaryCompletion":82,"completion":423,"start":424,"enrollment":425,"conditions":426,"interventions":430},[86],"2028-06-01","2026-06-01",8,[427,428,429,28],"Penetrating Keratoplasty","Multiple Graft Failure","Ocular Cicatricial Pemphigoid",[83],{"trials":432,"activeCount":97},[],{"trials":434,"activeCount":97},[],{"trials":436,"activeCount":97},[],{"trials":438,"activeCount":97},[],{"intervention":68,"totalTrials":93,"cells":440},{"EARLY_PHASE1":441,"PHASE1":443,"PHASE2":452,"PHASE3":454,"PHASE4":456,"NA":458},{"trials":442,"activeCount":97},[],{"trials":444,"activeCount":93,"soonestReadout":67},[445],{"nctId":65,"briefTitle":66,"status":262,"phases":446,"primaryCompletion":67,"completion":72,"start":447,"enrollment":448,"conditions":449,"interventions":451},[86],"2026-04-01",50,[200,450,32],"Proliferative Vitreo-Retinopathy",[68],{"trials":453,"activeCount":97},[],{"trials":455,"activeCount":97},[],{"trials":457,"activeCount":97},[],{"trials":459,"activeCount":97},[],{"intervention":461,"totalTrials":93,"cells":462},"Laryngeal sensory block with topical bupivacaine",{"EARLY_PHASE1":463,"PHASE1":476,"PHASE2":478,"PHASE3":480,"PHASE4":482,"NA":484},{"trials":464,"activeCount":93,"soonestReadout":469},[465],{"nctId":466,"briefTitle":467,"status":107,"phases":468,"primaryCompletion":469,"completion":469,"start":470,"enrollment":471,"conditions":472,"interventions":475},"NCT05216770","Understanding Disorder-specific Neural Pathophysiology in Laryngeal Dystonia and Voice Tremor",[85],"2027-08-31","2022-03-24",165,[473,18,474],"Laryngeal Dystonia","Tremor",[461],{"trials":477,"activeCount":97},[],{"trials":479,"activeCount":97},[],{"trials":481,"activeCount":97},[],{"trials":483,"activeCount":97},[],{"trials":485,"activeCount":97},[],{"intervention":487,"totalTrials":93,"cells":488},"Amoxicillin-Potassium Clavulanate",{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":493,"PHASE3":495,"PHASE4":497,"NA":509},{"trials":490,"activeCount":97},[],{"trials":492,"activeCount":97},[],{"trials":494,"activeCount":97},[],{"trials":496,"activeCount":97},[],{"trials":498,"activeCount":97},[499],{"nctId":500,"briefTitle":501,"status":181,"phases":502,"primaryCompletion":503,"completion":503,"start":504,"enrollment":505,"conditions":506,"interventions":508},"NCT01919411","Prophylactic Antibiotics After Functional Endoscopic Sinus Surgery: a Randomized, Double-blind Placebo Controlled Trial",[89],"2018-09","2013-02",134,[507],"Sinusitis",[487],{"trials":510,"activeCount":97},[],{"intervention":512,"totalTrials":93,"cells":513},"Normal Saline",{"EARLY_PHASE1":514,"PHASE1":516,"PHASE2":518,"PHASE3":520,"PHASE4":522,"NA":540},{"trials":515,"activeCount":97},[],{"trials":517,"activeCount":97},[],{"trials":519,"activeCount":97},[],{"trials":521,"activeCount":97},[],{"trials":523,"activeCount":97},[524],{"nctId":525,"briefTitle":526,"status":527,"phases":528,"primaryCompletion":529,"completion":530,"start":531,"enrollment":532,"conditions":533,"interventions":538},"NCT02162433","The Effect of Dexmedetomidine on Airway Complications After Deep or Awake Extubation","TERMINATED",[89],"2018-04","2018-04-23","2015-03",92,[534,535,536,537],"Adenotonsillar Hypertrophy","Obstructive Sleep Apnea","Tonsillitis","Adenoiditis",[512,539],"Dexmedetomidine",{"trials":541,"activeCount":97},[],{"intervention":539,"totalTrials":93,"cells":543},{"EARLY_PHASE1":544,"PHASE1":546,"PHASE2":548,"PHASE3":550,"PHASE4":552,"NA":558},{"trials":545,"activeCount":97},[],{"trials":547,"activeCount":97},[],{"trials":549,"activeCount":97},[],{"trials":551,"activeCount":97},[],{"trials":553,"activeCount":97},[554],{"nctId":525,"briefTitle":526,"status":527,"phases":555,"primaryCompletion":529,"completion":530,"start":531,"enrollment":532,"conditions":556,"interventions":557},[89],[534,535,536,537],[512,539],{"trials":559,"activeCount":97},[],{"intervention":561,"totalTrials":93,"cells":562},"Travoprost",{"EARLY_PHASE1":563,"PHASE1":565,"PHASE2":567,"PHASE3":569,"PHASE4":571,"NA":583},{"trials":564,"activeCount":97},[],{"trials":566,"activeCount":97},[],{"trials":568,"activeCount":97},[],{"trials":570,"activeCount":97},[],{"trials":572,"activeCount":97},[573],{"nctId":574,"briefTitle":575,"status":527,"phases":576,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":580,"interventions":581},"NCT01315574","Effects of Anti-Glaucoma Medications on the Ocular Surface",[89],"2013-12","2011-02",14,[15],[561,582],"Latanoprost",{"trials":584,"activeCount":97},[],{"intervention":582,"totalTrials":93,"cells":586},{"EARLY_PHASE1":587,"PHASE1":589,"PHASE2":591,"PHASE3":593,"PHASE4":595,"NA":601},{"trials":588,"activeCount":97},[],{"trials":590,"activeCount":97},[],{"trials":592,"activeCount":97},[],{"trials":594,"activeCount":97},[],{"trials":596,"activeCount":97},[597],{"nctId":574,"briefTitle":575,"status":527,"phases":598,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":599,"interventions":600},[89],[15],[561,582],{"trials":602,"activeCount":97},[],{"intervention":604,"totalTrials":93,"cells":605},"Loteprednol\u002Ftobramycin",{"EARLY_PHASE1":606,"PHASE1":608,"PHASE2":610,"PHASE3":612,"PHASE4":614,"NA":630},{"trials":607,"activeCount":97},[],{"trials":609,"activeCount":97},[],{"trials":611,"activeCount":97},[],{"trials":613,"activeCount":97},[],{"trials":615,"activeCount":97},[616],{"nctId":617,"briefTitle":618,"status":181,"phases":619,"primaryCompletion":620,"completion":621,"start":622,"enrollment":623,"conditions":624,"interventions":627},"NCT01456780","Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation\u002FMGD\u002FBlepharitis",[89],"2013-03","2017-06","2011-08",60,[625,626],"Meibomian Gland Dysfunction","Posterior Blepharitis",[604,628,629],"Loteprednol","B+L Advanced Eye Relief Lubricant Drop",{"trials":631,"activeCount":97},[],{"intervention":628,"totalTrials":93,"cells":633},{"EARLY_PHASE1":634,"PHASE1":636,"PHASE2":638,"PHASE3":640,"PHASE4":642,"NA":648},{"trials":635,"activeCount":97},[],{"trials":637,"activeCount":97},[],{"trials":639,"activeCount":97},[],{"trials":641,"activeCount":97},[],{"trials":643,"activeCount":97},[644],{"nctId":617,"briefTitle":618,"status":181,"phases":645,"primaryCompletion":620,"completion":621,"start":622,"enrollment":623,"conditions":646,"interventions":647},[89],[625,626],[604,628,629],{"trials":649,"activeCount":97},[],{"intervention":629,"totalTrials":93,"cells":651},{"EARLY_PHASE1":652,"PHASE1":654,"PHASE2":656,"PHASE3":658,"PHASE4":660,"NA":666},{"trials":653,"activeCount":97},[],{"trials":655,"activeCount":97},[],{"trials":657,"activeCount":97},[],{"trials":659,"activeCount":97},[],{"trials":661,"activeCount":97},[662],{"nctId":617,"briefTitle":618,"status":181,"phases":663,"primaryCompletion":620,"completion":621,"start":622,"enrollment":623,"conditions":664,"interventions":665},[89],[625,626],[604,628,629],{"trials":667,"activeCount":97},[],{"intervention":669,"totalTrials":93,"cells":670},"DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use",{"EARLY_PHASE1":671,"PHASE1":673,"PHASE2":675,"PHASE3":677,"PHASE4":679,"NA":691},{"trials":672,"activeCount":97},[],{"trials":674,"activeCount":97},[],{"trials":676,"activeCount":97},[],{"trials":678,"activeCount":97},[],{"trials":680,"activeCount":97},[681],{"nctId":682,"briefTitle":683,"status":684,"phases":685,"primaryCompletion":686,"completion":686,"start":687,"enrollment":97,"conditions":688,"interventions":690},"NCT04728646","Evaluation of Dextenza in Patients With Ocular GVHD and Effects on Ocular Surface Disease Outcomes","WITHDRAWN",[89],"2021-12-13","2021-09",[689],"Graft Vs Host Disease",[669],{"trials":692,"activeCount":97},[],{"intervention":694,"totalTrials":93,"cells":695},"Cyclosporine A 0.05%",{"EARLY_PHASE1":696,"PHASE1":698,"PHASE2":700,"PHASE3":702,"PHASE4":704,"NA":716},{"trials":697,"activeCount":97},[],{"trials":699,"activeCount":97},[],{"trials":701,"activeCount":97},[],{"trials":703,"activeCount":97},[],{"trials":705,"activeCount":97},[706],{"nctId":707,"briefTitle":708,"status":527,"phases":709,"primaryCompletion":710,"completion":710,"start":711,"enrollment":425,"conditions":712,"interventions":714},"NCT00553735","The Prophylactic Use of Topical Cyclosporine A 0.05% to Prevent Graft Versus Host Disease Related Dry Eye",[89],"2010-12","2007-08",[713],"Dry Eye",[694,715],"Arificial Tear",{"trials":717,"activeCount":97},[],{"intervention":715,"totalTrials":93,"cells":719},{"EARLY_PHASE1":720,"PHASE1":722,"PHASE2":724,"PHASE3":726,"PHASE4":728,"NA":734},{"trials":721,"activeCount":97},[],{"trials":723,"activeCount":97},[],{"trials":725,"activeCount":97},[],{"trials":727,"activeCount":97},[],{"trials":729,"activeCount":97},[730],{"nctId":707,"briefTitle":708,"status":527,"phases":731,"primaryCompletion":710,"completion":710,"start":711,"enrollment":425,"conditions":732,"interventions":733},[89],[713],[694,715],{"trials":735,"activeCount":97},[],{"intervention":737,"totalTrials":93,"cells":738},"ReNu MultiPlus® MultiPurpose Solution",{"EARLY_PHASE1":739,"PHASE1":741,"PHASE2":743,"PHASE3":745,"PHASE4":747,"NA":763},{"trials":740,"activeCount":97},[],{"trials":742,"activeCount":97},[],{"trials":744,"activeCount":97},[],{"trials":746,"activeCount":97},[],{"trials":748,"activeCount":97},[749],{"nctId":750,"briefTitle":751,"status":181,"phases":752,"primaryCompletion":753,"completion":754,"start":755,"enrollment":756,"conditions":757,"interventions":760},"NCT01250925","Effect of Contact Lens Wear on Immune Cell Density and Morphology of the Ocular Surface",[89],"2012-02","2012-07","2010-08",94,[758,759],"Myopia","Refractive Error",[737,761,762],"OPTI-FREE® RepleniSH®","Clear Care®",{"trials":764,"activeCount":97},[],{"intervention":761,"totalTrials":93,"cells":766},{"EARLY_PHASE1":767,"PHASE1":769,"PHASE2":771,"PHASE3":773,"PHASE4":775,"NA":781},{"trials":768,"activeCount":97},[],{"trials":770,"activeCount":97},[],{"trials":772,"activeCount":97},[],{"trials":774,"activeCount":97},[],{"trials":776,"activeCount":97},[777],{"nctId":750,"briefTitle":751,"status":181,"phases":778,"primaryCompletion":753,"completion":754,"start":755,"enrollment":756,"conditions":779,"interventions":780},[89],[758,759],[737,761,762],{"trials":782,"activeCount":97},[],{"intervention":762,"totalTrials":93,"cells":784},{"EARLY_PHASE1":785,"PHASE1":787,"PHASE2":789,"PHASE3":791,"PHASE4":793,"NA":799},{"trials":786,"activeCount":97},[],{"trials":788,"activeCount":97},[],{"trials":790,"activeCount":97},[],{"trials":792,"activeCount":97},[],{"trials":794,"activeCount":97},[795],{"nctId":750,"briefTitle":751,"status":181,"phases":796,"primaryCompletion":753,"completion":754,"start":755,"enrollment":756,"conditions":797,"interventions":798},[89],[758,759],[737,761,762],{"trials":800,"activeCount":97},[],{"intervention":802,"totalTrials":26,"cells":803},"Acetaminophen",{"EARLY_PHASE1":804,"PHASE1":806,"PHASE2":817,"PHASE3":830,"PHASE4":842,"NA":844},{"trials":805,"activeCount":97},[],{"trials":807,"activeCount":97},[808],{"nctId":809,"briefTitle":810,"status":684,"phases":811,"primaryCompletion":812,"completion":812,"start":503,"enrollment":97,"conditions":813,"interventions":815},"NCT03385057","Postoperative Ibuprofen Use and Risk of Bleeding in Pediatric Tonsillectomy",[86],"2023-01-01",[814],"Tonsillectomy With or Without Adenoidectomy",[816,802],"Ibuprofen",{"trials":818,"activeCount":97},[819],{"nctId":820,"briefTitle":821,"status":181,"phases":822,"primaryCompletion":823,"completion":823,"start":824,"enrollment":825,"conditions":826,"interventions":829},"NCT01605903","Postoperative Ibuprofen and the Risk of Bleeding After Tonsillectomy With or Without Adenoidectomy",[87],"2017-02-15","2012-05-03",741,[827,828],"Tonsillectomy","Adenoidectomy",[816,802],{"trials":831,"activeCount":97},[832],{"nctId":833,"briefTitle":834,"status":835,"phases":836,"primaryCompletion":837,"completion":837,"start":838,"enrollment":839,"conditions":840,"interventions":841},"NCT03295214","Acetaminophen Given Per Os and Intravenous in Sinus Surgery","UNKNOWN",[88],"2020-03","2018-03-28",124,[802],[802],{"trials":843,"activeCount":97},[],{"trials":845,"activeCount":97},[],{"intervention":847,"totalTrials":174,"cells":848},"Methylprednisolone Sodium Succinate",{"EARLY_PHASE1":849,"PHASE1":851,"PHASE2":863,"PHASE3":865,"PHASE4":880,"NA":882},{"trials":850,"activeCount":97},[],{"trials":852,"activeCount":97},[853],{"nctId":854,"briefTitle":855,"status":181,"phases":856,"primaryCompletion":857,"completion":857,"start":577,"enrollment":858,"conditions":859,"interventions":861},"NCT01977781","Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease",[86],"2014-09",40,[860],"Ocular GVHD",[862,847],"Tacrolimus",{"trials":864,"activeCount":97},[],{"trials":866,"activeCount":97},[867],{"nctId":868,"briefTitle":869,"status":181,"phases":870,"primaryCompletion":871,"completion":872,"start":873,"enrollment":874,"conditions":875,"interventions":877},"NCT00097448","Sudden Deafness Treatment Trial",[88],"2009-10","2011-03","2004-12",255,[876],"Sudden Deafness",[878,879],"prednisone","methylprednisolone sodium succinate",{"trials":881,"activeCount":97},[],{"trials":883,"activeCount":97},[],{"intervention":885,"totalTrials":93,"cells":886},"Propranolol",{"EARLY_PHASE1":887,"PHASE1":889,"PHASE2":891,"PHASE3":893,"PHASE4":904,"NA":906},{"trials":888,"activeCount":97},[],{"trials":890,"activeCount":97},[],{"trials":892,"activeCount":97},[],{"trials":894,"activeCount":97},[895],{"nctId":896,"briefTitle":897,"status":684,"phases":898,"primaryCompletion":899,"completion":899,"start":900,"enrollment":97,"conditions":901,"interventions":903},"NCT01058317","Propranolol Administration in Pediatric Patients With Recurrent Respiratory Papillomatosis",[87,88],"2010-09","2010-01",[902],"Recurrent Respiratory Papillomatosis",[885],{"trials":905,"activeCount":97},[],{"trials":907,"activeCount":97},[],{"intervention":909,"totalTrials":93,"cells":910},"Fluorometholone 0.1% Oph Susp",{"EARLY_PHASE1":911,"PHASE1":913,"PHASE2":915,"PHASE3":917,"PHASE4":934,"NA":936},{"trials":912,"activeCount":97},[],{"trials":914,"activeCount":97},[],{"trials":916,"activeCount":97},[],{"trials":918,"activeCount":97},[919],{"nctId":920,"briefTitle":921,"status":181,"phases":922,"primaryCompletion":923,"completion":923,"start":924,"enrollment":925,"conditions":926,"interventions":932},"NCT04149210","FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial",[88],"2024-11-30","2021-08-19",2410,[927,928,929,930,931],"Trachomatous Trichiasis (TT)","Eye Diseases","Eyelid Diseases","Trachomatous","Trichiasis",[909,933],"Artificial Tears",{"trials":935,"activeCount":97},[],{"trials":937,"activeCount":97},[],{"intervention":933,"totalTrials":93,"cells":939},{"EARLY_PHASE1":940,"PHASE1":942,"PHASE2":944,"PHASE3":946,"PHASE4":952,"NA":954},{"trials":941,"activeCount":97},[],{"trials":943,"activeCount":97},[],{"trials":945,"activeCount":97},[],{"trials":947,"activeCount":97},[948],{"nctId":920,"briefTitle":921,"status":181,"phases":949,"primaryCompletion":923,"completion":923,"start":924,"enrollment":925,"conditions":950,"interventions":951},[88],[927,928,929,930,931],[909,933],{"trials":953,"activeCount":97},[],{"trials":955,"activeCount":97},[],{"intervention":957,"totalTrials":93,"cells":958},"Proton Pump Inhibitor",{"EARLY_PHASE1":959,"PHASE1":961,"PHASE2":963,"PHASE3":965,"PHASE4":977,"NA":979},{"trials":960,"activeCount":97},[],{"trials":962,"activeCount":97},[],{"trials":964,"activeCount":97},[],{"trials":966,"activeCount":97},[967],{"nctId":968,"briefTitle":969,"status":684,"phases":970,"primaryCompletion":971,"completion":971,"start":972,"enrollment":97,"conditions":973,"interventions":976},"NCT00771706","Longitudinal Study of Children With a Chronic Cough and the Impact of Gastroesophageal Reflux",[88],"2008-10","2006-01",[974,975],"Cough","Gastroesophageal Reflux",[957],{"trials":978,"activeCount":97},[],{"trials":980,"activeCount":97},[],{"intervention":878,"totalTrials":93,"cells":982},{"EARLY_PHASE1":983,"PHASE1":985,"PHASE2":987,"PHASE3":989,"PHASE4":995,"NA":997},{"trials":984,"activeCount":97},[],{"trials":986,"activeCount":97},[],{"trials":988,"activeCount":97},[],{"trials":990,"activeCount":97},[991],{"nctId":868,"briefTitle":869,"status":181,"phases":992,"primaryCompletion":871,"completion":872,"start":873,"enrollment":874,"conditions":993,"interventions":994},[88],[876],[878,879],{"trials":996,"activeCount":97},[],{"trials":998,"activeCount":97},[],{"intervention":816,"totalTrials":174,"cells":1000},{"EARLY_PHASE1":1001,"PHASE1":1003,"PHASE2":1009,"PHASE3":1015,"PHASE4":1017,"NA":1019},{"trials":1002,"activeCount":97},[],{"trials":1004,"activeCount":97},[1005],{"nctId":809,"briefTitle":810,"status":684,"phases":1006,"primaryCompletion":812,"completion":812,"start":503,"enrollment":97,"conditions":1007,"interventions":1008},[86],[814],[816,802],{"trials":1010,"activeCount":97},[1011],{"nctId":820,"briefTitle":821,"status":181,"phases":1012,"primaryCompletion":823,"completion":823,"start":824,"enrollment":825,"conditions":1013,"interventions":1014},[87],[827,828],[816,802],{"trials":1016,"activeCount":97},[],{"trials":1018,"activeCount":97},[],{"trials":1020,"activeCount":97},[],{"intervention":1022,"totalTrials":93,"cells":1023},"Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept",{"EARLY_PHASE1":1024,"PHASE1":1026,"PHASE2":1028,"PHASE3":1042,"PHASE4":1044,"NA":1046},{"trials":1025,"activeCount":97},[],{"trials":1027,"activeCount":97},[],{"trials":1029,"activeCount":97},[1030],{"nctId":1031,"briefTitle":1032,"status":181,"phases":1033,"primaryCompletion":1034,"completion":1034,"start":1035,"enrollment":1036,"conditions":1037,"interventions":1039},"NCT04311606","Anti-VEGF Therapy for Acute Thyroid Eye Disease",[87],"2024-12-17","2020-11-02",11,[1038],"Thyroid Eye Disease",[1022,1040,1041],"Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept","Sub-tenon injection of hyaluronidase (HA) alone",{"trials":1043,"activeCount":97},[],{"trials":1045,"activeCount":97},[],{"trials":1047,"activeCount":97},[],{"intervention":1040,"totalTrials":93,"cells":1049},{"EARLY_PHASE1":1050,"PHASE1":1052,"PHASE2":1054,"PHASE3":1060,"PHASE4":1062,"NA":1064},{"trials":1051,"activeCount":97},[],{"trials":1053,"activeCount":97},[],{"trials":1055,"activeCount":97},[1056],{"nctId":1031,"briefTitle":1032,"status":181,"phases":1057,"primaryCompletion":1034,"completion":1034,"start":1035,"enrollment":1036,"conditions":1058,"interventions":1059},[87],[1038],[1022,1040,1041],{"trials":1061,"activeCount":97},[],{"trials":1063,"activeCount":97},[],{"trials":1065,"activeCount":97},[],{"intervention":1041,"totalTrials":93,"cells":1067},{"EARLY_PHASE1":1068,"PHASE1":1070,"PHASE2":1072,"PHASE3":1078,"PHASE4":1080,"NA":1082},{"trials":1069,"activeCount":97},[],{"trials":1071,"activeCount":97},[],{"trials":1073,"activeCount":97},[1074],{"nctId":1031,"briefTitle":1032,"status":181,"phases":1075,"primaryCompletion":1034,"completion":1034,"start":1035,"enrollment":1036,"conditions":1076,"interventions":1077},[87],[1038],[1022,1040,1041],{"trials":1079,"activeCount":97},[],{"trials":1081,"activeCount":97},[],{"trials":1083,"activeCount":97},[],{"intervention":1085,"totalTrials":93,"cells":1086},"Infliximab",{"EARLY_PHASE1":1087,"PHASE1":1089,"PHASE2":1091,"PHASE3":1101,"PHASE4":1103,"NA":1105},{"trials":1088,"activeCount":97},[],{"trials":1090,"activeCount":97},[],{"trials":1092,"activeCount":97},[1093],{"nctId":1094,"briefTitle":1095,"status":684,"phases":1096,"primaryCompletion":1097,"completion":1097,"start":710,"enrollment":97,"conditions":1098,"interventions":1100},"NCT01256489","Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome\u002F Toxic Epidermal Necrolysis (SJS\u002FTENS)",[86,87],"2015-01",[28,1099],"Corneal Blindness",[1085],{"trials":1102,"activeCount":97},[],{"trials":1104,"activeCount":97},[],{"trials":1106,"activeCount":97},[],{"intervention":1108,"totalTrials":93,"cells":1109},"Cultivation of Limbal epithelial cells into a graft",{"EARLY_PHASE1":1110,"PHASE1":1112,"PHASE2":1114,"PHASE3":1126,"PHASE4":1128,"NA":1130},{"trials":1111,"activeCount":97},[],{"trials":1113,"activeCount":97},[],{"trials":1115,"activeCount":97},[1116],{"nctId":1117,"briefTitle":1118,"status":181,"phases":1119,"primaryCompletion":1120,"completion":1120,"start":1121,"enrollment":1122,"conditions":1123,"interventions":1125},"NCT02592330","Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft",[86,87],"2023-03-31","2016-08-01",23,[1124],"Limbal Stem Cell Deficiency",[1108],{"trials":1127,"activeCount":97},[],{"trials":1129,"activeCount":97},[],{"trials":1131,"activeCount":97},[],{"intervention":1133,"totalTrials":93,"cells":1134},"5-Fluorouracil",{"EARLY_PHASE1":1135,"PHASE1":1137,"PHASE2":1139,"PHASE3":1151,"PHASE4":1153,"NA":1155},{"trials":1136,"activeCount":97},[],{"trials":1138,"activeCount":97},[],{"trials":1140,"activeCount":97},[1141],{"nctId":1142,"briefTitle":1143,"status":181,"phases":1144,"primaryCompletion":1145,"completion":1145,"start":1146,"enrollment":93,"conditions":1147,"interventions":1150},"NCT02705352","5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts",[87],"2019-01-25","2016-08-25",[1148,1149],"Ectropion","Skin Neoplasms",[1133],{"trials":1152,"activeCount":97},[],{"trials":1154,"activeCount":97},[],{"trials":1156,"activeCount":97},[],{"intervention":1158,"totalTrials":93,"cells":1159},"4-aminopyridine",{"EARLY_PHASE1":1160,"PHASE1":1162,"PHASE2":1164,"PHASE3":1179,"PHASE4":1181,"NA":1183},{"trials":1161,"activeCount":97},[],{"trials":1163,"activeCount":97},[],{"trials":1165,"activeCount":97},[1166],{"nctId":1167,"briefTitle":1168,"status":684,"phases":1169,"primaryCompletion":1170,"completion":1171,"start":1172,"enrollment":97,"conditions":1173,"interventions":1177},"NCT03578354","4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine",[87],"2023-01","2024-08","2019-01",[1174,1175,1176],"Vestibular Migraine","Migraine Disorders","Vestibular Diseases",[1158,1178],"Atenolol",{"trials":1180,"activeCount":97},[],{"trials":1182,"activeCount":97},[],{"trials":1184,"activeCount":97},[],{"intervention":1178,"totalTrials":93,"cells":1186},{"EARLY_PHASE1":1187,"PHASE1":1189,"PHASE2":1191,"PHASE3":1197,"PHASE4":1199,"NA":1201},{"trials":1188,"activeCount":97},[],{"trials":1190,"activeCount":97},[],{"trials":1192,"activeCount":97},[1193],{"nctId":1167,"briefTitle":1168,"status":684,"phases":1194,"primaryCompletion":1170,"completion":1171,"start":1172,"enrollment":97,"conditions":1195,"interventions":1196},[87],[1174,1175,1176],[1158,1178],{"trials":1198,"activeCount":97},[],{"trials":1200,"activeCount":97},[],{"trials":1202,"activeCount":97},[],{"intervention":1204,"totalTrials":93,"cells":1205},"ranibizumab",{"EARLY_PHASE1":1206,"PHASE1":1208,"PHASE2":1220,"PHASE3":1222,"PHASE4":1224,"NA":1226},{"trials":1207,"activeCount":97},[],{"trials":1209,"activeCount":97},[1210],{"nctId":1211,"briefTitle":1212,"status":181,"phases":1213,"primaryCompletion":1214,"completion":1215,"start":1216,"enrollment":858,"conditions":1217,"interventions":1219},"NCT00765921","Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma",[86],"2016-02","2016-09","2008-06",[1218],"Choroidal Melanoma",[1204],{"trials":1221,"activeCount":97},[],{"trials":1223,"activeCount":97},[],{"trials":1225,"activeCount":97},[],{"trials":1227,"activeCount":97},[],{"intervention":1229,"totalTrials":93,"cells":1230},"Topical Avastin 1%",{"EARLY_PHASE1":1231,"PHASE1":1233,"PHASE2":1245,"PHASE3":1247,"PHASE4":1249,"NA":1251},{"trials":1232,"activeCount":97},[],{"trials":1234,"activeCount":97},[1235],{"nctId":1236,"briefTitle":1237,"status":181,"phases":1238,"primaryCompletion":1239,"completion":1239,"start":1240,"enrollment":1241,"conditions":1242,"interventions":1244},"NCT00559936","Topical Avastin for Treatment of Corneal Neovascularization",[86],"2010-10","2007-02",24,[1243],"Corneal Neovascularization",[1229],{"trials":1246,"activeCount":97},[],{"trials":1248,"activeCount":97},[],{"trials":1250,"activeCount":97},[],{"trials":1252,"activeCount":97},[],{"intervention":862,"totalTrials":93,"cells":1254},{"EARLY_PHASE1":1255,"PHASE1":1257,"PHASE2":1263,"PHASE3":1265,"PHASE4":1267,"NA":1269},{"trials":1256,"activeCount":97},[],{"trials":1258,"activeCount":97},[1259],{"nctId":854,"briefTitle":855,"status":181,"phases":1260,"primaryCompletion":857,"completion":857,"start":577,"enrollment":858,"conditions":1261,"interventions":1262},[86],[860],[862,847],{"trials":1264,"activeCount":97},[],{"trials":1266,"activeCount":97},[],{"trials":1268,"activeCount":97},[],{"trials":1270,"activeCount":97},[],{"intervention":1272,"totalTrials":93,"cells":1273},"Latanoprost eluting contact lens",{"EARLY_PHASE1":1274,"PHASE1":1276,"PHASE2":1288,"PHASE3":1290,"PHASE4":1292,"NA":1294},{"trials":1275,"activeCount":97},[],{"trials":1277,"activeCount":97},[1278],{"nctId":1279,"briefTitle":1280,"status":527,"phases":1281,"primaryCompletion":1282,"completion":1282,"start":1283,"enrollment":93,"conditions":1284,"interventions":1286},"NCT04500574","Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension",[86],"2025-10-10","2024-04-03",[15,1285],"Ocular Hypertension",[1272,1287],"Topical Latanoprost",{"trials":1289,"activeCount":97},[],{"trials":1291,"activeCount":97},[],{"trials":1293,"activeCount":97},[],{"trials":1295,"activeCount":97},[],{"intervention":1287,"totalTrials":93,"cells":1297},{"EARLY_PHASE1":1298,"PHASE1":1300,"PHASE2":1306,"PHASE3":1308,"PHASE4":1310,"NA":1312},{"trials":1299,"activeCount":97},[],{"trials":1301,"activeCount":97},[1302],{"nctId":1279,"briefTitle":1280,"status":527,"phases":1303,"primaryCompletion":1282,"completion":1282,"start":1283,"enrollment":93,"conditions":1304,"interventions":1305},[86],[15,1285],[1272,1287],{"trials":1307,"activeCount":97},[],{"trials":1309,"activeCount":97},[],{"trials":1311,"activeCount":97},[],{"trials":1313,"activeCount":97},[],{"intervention":1315,"totalTrials":93,"cells":1316},"Brimonidine, pilocarpine",{"EARLY_PHASE1":1317,"PHASE1":1331,"PHASE2":1333,"PHASE3":1335,"PHASE4":1337,"NA":1339},{"trials":1318,"activeCount":97},[1319],{"nctId":1320,"briefTitle":1321,"status":835,"phases":1322,"primaryCompletion":1323,"completion":1324,"start":1325,"enrollment":1326,"conditions":1327,"interventions":1330},"NCT03825081","Pilocarpine and Brimonidine in Patients With Monofocal Lenses",[85],"2019-09-01","2019-12-31","2019-01-21",33,[1328,1329],"Presbyopia","Pseudophakia",[1315],{"trials":1332,"activeCount":97},[],{"trials":1334,"activeCount":97},[],{"trials":1336,"activeCount":97},[],{"trials":1338,"activeCount":97},[],{"trials":1340,"activeCount":97},[],{"intervention":1342,"totalTrials":93,"cells":1343},"AR-42",{"EARLY_PHASE1":1344,"PHASE1":1356,"PHASE2":1358,"PHASE3":1360,"PHASE4":1362,"NA":1364},{"trials":1345,"activeCount":97},[1346],{"nctId":1347,"briefTitle":1348,"status":527,"phases":1349,"primaryCompletion":1350,"completion":1351,"start":1352,"enrollment":16,"conditions":1353,"interventions":1355},"NCT02282917","Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma",[85],"2017-05-30","2021-01-04","2015-12",[23,1354,244,222],"Meningioma",[1342],{"trials":1357,"activeCount":97},[],{"trials":1359,"activeCount":97},[],{"trials":1361,"activeCount":97},[],{"trials":1363,"activeCount":97},[],{"trials":1365,"activeCount":97},[],{"intervention":1367,"totalTrials":93,"cells":1368},"Netarsudil 0.02% Ophthalmic Solution",{"EARLY_PHASE1":1369,"PHASE1":1381,"PHASE2":1383,"PHASE3":1385,"PHASE4":1387,"NA":1389},{"trials":1370,"activeCount":97},[1371],{"nctId":1372,"briefTitle":1373,"status":181,"phases":1374,"primaryCompletion":1375,"completion":1375,"start":1376,"enrollment":1377,"conditions":1378,"interventions":1380},"NCT04057053","Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty",[85],"2020-12-20","2018-10-02",10,[188,1379],"Cataract",[1367],{"trials":1382,"activeCount":97},[],{"trials":1384,"activeCount":97},[],{"trials":1386,"activeCount":97},[],{"trials":1388,"activeCount":97},[],{"trials":1390,"activeCount":97},[],{"intervention":1392,"totalTrials":93,"cells":1393},"Dorzolamide 2%-timolol 0.5%",{"EARLY_PHASE1":1394,"PHASE1":1396,"PHASE2":1398,"PHASE3":1400,"PHASE4":1402,"NA":1404},{"trials":1395,"activeCount":97},[],{"trials":1397,"activeCount":97},[],{"trials":1399,"activeCount":97},[],{"trials":1401,"activeCount":97},[],{"trials":1403,"activeCount":97},[],{"trials":1405,"activeCount":97},[1406],{"nctId":1407,"briefTitle":1408,"status":181,"phases":1409,"primaryCompletion":1410,"completion":1410,"start":1411,"enrollment":371,"conditions":1412,"interventions":1413},"NCT00824824","Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)",[90],"2012-08","2009-01",[15],[1392,1414],"Brimonidine 0.2%-0.5% timolol 0.5",{"intervention":1414,"totalTrials":93,"cells":1416},{"EARLY_PHASE1":1417,"PHASE1":1419,"PHASE2":1421,"PHASE3":1423,"PHASE4":1425,"NA":1427},{"trials":1418,"activeCount":97},[],{"trials":1420,"activeCount":97},[],{"trials":1422,"activeCount":97},[],{"trials":1424,"activeCount":97},[],{"trials":1426,"activeCount":97},[],{"trials":1428,"activeCount":97},[1429],{"nctId":1407,"briefTitle":1408,"status":181,"phases":1430,"primaryCompletion":1410,"completion":1410,"start":1411,"enrollment":371,"conditions":1431,"interventions":1432},[90],[15],[1392,1414],{"intervention":1434,"totalTrials":93,"cells":1435},"Mucinex®",{"EARLY_PHASE1":1436,"PHASE1":1438,"PHASE2":1440,"PHASE3":1442,"PHASE4":1444,"NA":1446},{"trials":1437,"activeCount":97},[],{"trials":1439,"activeCount":97},[],{"trials":1441,"activeCount":97},[],{"trials":1443,"activeCount":97},[],{"trials":1445,"activeCount":97},[],{"trials":1447,"activeCount":97},[1448],{"nctId":1449,"briefTitle":1450,"status":181,"phases":1451,"primaryCompletion":1452,"completion":1452,"start":1215,"enrollment":1453,"conditions":1454,"interventions":1456},"NCT02859246","Mucinex® for Treatment of Filamentary Keratitis",[90],"2018-07",15,[1455],"Filamentary Keratitis",[1434],{"intervention":1458,"totalTrials":93,"cells":1459},"Bevacizumab",{"EARLY_PHASE1":1460,"PHASE1":1462,"PHASE2":1464,"PHASE3":1466,"PHASE4":1468,"NA":1470},{"trials":1461,"activeCount":97},[],{"trials":1463,"activeCount":97},[],{"trials":1465,"activeCount":97},[],{"trials":1467,"activeCount":97},[],{"trials":1469,"activeCount":97},[],{"trials":1471,"activeCount":97},[1472],{"nctId":1473,"briefTitle":1474,"status":684,"phases":1475,"primaryCompletion":620,"completion":1476,"start":755,"enrollment":97,"conditions":1477,"interventions":1485},"NCT01256580","Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD",[90],"2013-09",[1478,758,1479,1480,1481,1482,1483,1484],"Choroidal Neovascularization","Punctate Inner Choroidopathy (PIC)","Multifocal Choroiditis","Ocular Histoplasmosis Syndrome","Central Serous Chorioretinopathy (CSC)","Angioid Streaks","Trauma, or Hereditary Eye Diseases",[1458,1486],"Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy",{"intervention":1486,"totalTrials":93,"cells":1488},{"EARLY_PHASE1":1489,"PHASE1":1491,"PHASE2":1493,"PHASE3":1495,"PHASE4":1497,"NA":1499},{"trials":1490,"activeCount":97},[],{"trials":1492,"activeCount":97},[],{"trials":1494,"activeCount":97},[],{"trials":1496,"activeCount":97},[],{"trials":1498,"activeCount":97},[],{"trials":1500,"activeCount":97},[1501],{"nctId":1473,"briefTitle":1474,"status":684,"phases":1502,"primaryCompletion":620,"completion":1476,"start":755,"enrollment":97,"conditions":1503,"interventions":1504},[90],[1478,758,1479,1480,1481,1482,1483,1484],[1458,1486],{"intervention":1506,"totalTrials":93,"cells":1507},"brimonidine 0.15%",{"EARLY_PHASE1":1508,"PHASE1":1510,"PHASE2":1512,"PHASE3":1514,"PHASE4":1516,"NA":1518},{"trials":1509,"activeCount":97},[],{"trials":1511,"activeCount":97},[],{"trials":1513,"activeCount":97},[],{"trials":1515,"activeCount":97},[],{"trials":1517,"activeCount":97},[],{"trials":1519,"activeCount":97},[1520],{"nctId":1521,"briefTitle":1522,"status":181,"phases":1523,"primaryCompletion":1524,"completion":1524,"start":1525,"enrollment":1526,"conditions":1527,"interventions":1528},"NCT01105065","Effect of Alphagan on Retinal Blood Flow Autoregulation and Motion Detection in Patients With Normal Pressure Glaucoma",[90],"2012-09","2010-03",46,[15],[1506]]